Top Page
CardieX
(Sydney:CDX)
CardieX (CDX) vs. S&P 500 (SPY)
CardieX Business Overview & Revenue Model
CardieX Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 10.91M | 4.60M | 4.07M | 5.00M | 4.29M | Gross Profit |
| 10.11M | 3.70M | 3.13M | 4.10M | 3.59M | EBIT |
| -4.63M | -15.35M | -12.66M | -4.86M | -3.67M | EBITDA |
| -5.35M | -18.98M | -11.36M | -5.19M | -3.37M | Net Income Common Stockholders |
| -6.77M | -19.06M | -11.38M | -5.55M | -3.32M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 5.35M | 6.27M | 2.50M | 5.20M | 2.79M | Total Assets |
| 12.65M | 14.30M | 12.38M | 11.26M | 10.68M | Total Debt |
| 3.86M | 2.11M | 2.07M | 1.17M | 2.24M | Net Debt |
| 3.38M | 1.40M | 613.88K | -2.50M | 174.69K | Total Liabilities |
| 8.56M | 15.30M | 5.77M | 3.35M | 4.80M | Stockholders Equity |
| 4.09M | -1.00M | 6.61M | 7.91M | 5.88M |
| Cash Flow | Free Cash Flow | |||
| -7.84M | -12.08M | -10.06M | -4.33M | -1.91M | Operating Cash Flow |
| -7.72M | -12.00M | -9.62M | -3.97M | -1.70M | Investing Cash Flow |
| -118.41K | -80.28K | -438.06K | 363.16K | -3.70M | Financing Cash Flow |
| 7.59M | 11.35M | 7.41M | 5.29M | 2.47M |
CardieX Technical Analysis
CardieX Peers Comparison
CardieX Corporate Events
Cardiex Limited held an Extraordinary General Meeting where all proposed resolutions were successfully passed by poll. The resolutions included the ratification of prior issues of placement shares and options, approval of participation in placements, and long-term incentives for directors and employees, indicating strong shareholder support and strategic alignment with the company’s growth plans.
CardieX has reported strong sales momentum for its CONNEQT Pulse device, with approximately 3,000 units sold or under contract since its launch in mid-January. The company is also enhancing its digital ecosystem with the CONNEQT App’s new Cardiology Report feature, which aims to increase user engagement and drive future revenue through premium offerings. Despite regulatory delays in the U.S. and the impact of tariffs, CardieX is optimizing operations by consolidating R&D in Sydney, achieving cost savings and operational efficiencies. The company is preparing for the Australian launch of the Pulse and anticipates significant sales growth in the coming months.
CardieX Limited reported its quarterly cash flow, highlighting a net cash outflow from operating activities of $2.058 million, primarily due to substantial staff and administrative costs. Despite a challenging quarter, the company secured $250,000 from C2 Ventures Funding Commitment Agreement and other share applications, contributing to a net cash inflow from financing activities of $7.923 million year-to-date, which could bolster its financial position and support ongoing operations.
CardieX Limited has announced an Extraordinary General Meeting scheduled for May 9, 2025, at their Millers Point location. Shareholders are encouraged to participate in the meeting either in person or by proxy, with the company promoting paperless communication by urging shareholders to access documents online.
Cardiex Limited announced that its CONNEQT Health subsidiary has integrated its health monitoring capabilities with the Apple Health app on iPhone, allowing users to access key arterial health biomarkers directly. This integration enhances the user experience by providing a more connected and personalized healthcare experience, enabling patients to manage their health more effectively and securely.
Cardiex Limited has launched a new Cardiology Report feature in its CONNEQT App, now available on the Apple App Store. This update enhances the app by providing users with a comprehensive cardiovascular health assessment, translating clinically validated biomarkers into an easy-to-understand format. The feature is designed for proactive heart health management, enabling users to track cardiovascular indicators, identify risks, and make informed decisions. It is expected to increase user engagement and lays the groundwork for future monetization opportunities, reinforcing Cardiex’s leadership in digital heart health transformation.
Cardiex Limited reported a significant decrease in revenues by 83% for the half-year ending December 31, 2024, compared to the same period in 2023, resulting in a net loss of $6,973,605. This financial downturn marks a stark contrast to the previous year’s profit, reflecting challenges that may impact the company’s market positioning and stakeholder confidence.
CardieX Limited (ASX: CDX) addressed a recent inquiry from the ASX regarding a notable price increase in its securities from $0.115 to $0.155. The company confirmed that it is not aware of any undisclosed information that could explain the trading activity and affirmed compliance with relevant listing rules. This statement reassures stakeholders about the transparency of the company’s operations, maintaining market confidence despite the unexpected price fluctuations.